Relapsed/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse
P Bhatt, C Kloock, R Comenzo - Current Oncology, 2023 - mdpi.com
Multiple myeloma remains an incurable disease with the usual disease course requiring
induction therapy, autologous stem cell transplantation for eligible patients, and long-term …
induction therapy, autologous stem cell transplantation for eligible patients, and long-term …
Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial
P Sonneveld, A Chanan-Khan, K Weisel… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months),
daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged …
daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged …
Management of relapsed–refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice
Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
NK cell phenotype is associated with response and resistance to daratumumab in relapsed/refractory multiple myeloma
CPM Verkleij, KA Frerichs, MEC Broekmans… - …, 2023 - journals.lww.com
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM).
Natural killer (NK) cells play an important role during daratumumab therapy by mediating …
Natural killer (NK) cells play an important role during daratumumab therapy by mediating …
Past, present, and a glance into the future of multiple myeloma treatment
Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone
marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The …
marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The …
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing …
E Eleutherakis Papaiakovou, E Terpos… - Leukemia & …, 2023 - Taylor & Francis
Autologous stem cell transplantation (ASCT) remains a standard therapy for multiple
myeloma (MM) patients. Our study aimed to assess the impact of daratumumab-containing …
myeloma (MM) patients. Our study aimed to assess the impact of daratumumab-containing …
Breaking through multiple myeloma: a paradigm for a comprehensive tumor ecosystem targeting
Multiple myeloma (MM) is a cancerous condition characterized by the proliferation of plasma
cells within the hematopoietic marrow, resulting in multiple osteolytic lesions. MM patients …
cells within the hematopoietic marrow, resulting in multiple osteolytic lesions. MM patients …
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: a real‐world multicentre UK retrospective analysis
A McMillan, S Basu, K Karunanithi… - British Journal of …, 2023 - Wiley Online Library
Daratumumab, bortezomib and dexamethasone (DVd) is approved for patients with
relapsed multiple myeloma following the CASTOR phase 3 clinical trial. This retrospective …
relapsed multiple myeloma following the CASTOR phase 3 clinical trial. This retrospective …
[HTML][HTML] 达雷妥尤单抗在多发性骨髓瘤中的应用
贺玉钦， 陈文明 - 临床血液学杂志, 2023 - lcxy.whuhzzs.com
达雷妥尤单抗是一种新型人源化抗CD38 单克隆抗体, 可靶向治疗多发性骨髓瘤(multiple
myeloma, MM) 瘤细胞表面的CD38, 直接杀伤肿瘤细胞和通过调节免疫微环境双重作用机制 …
myeloma, MM) 瘤细胞表面的CD38, 直接杀伤肿瘤细胞和通过调节免疫微环境双重作用机制 …
[HTML][HTML] Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States
R Fonseca, EE Chinaeke, N Gupta-Werner… - … : Innovations, Quality & …, 2023 - Elsevier
Daratumumab (DARA) is an anti-CD38 monoclonal antibody approved as a combination
therapy for newly diagnosed multiple myeloma (MM) and as monotherapy and combination …
therapy for newly diagnosed multiple myeloma (MM) and as monotherapy and combination …